您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > HDAC1/2 and CDK2-IN-1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
HDAC1/2 and CDK2-IN-1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
HDAC1/2 and CDK2-IN-1图片
CAS NO:2418559-01-8
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
HDAC1/2 and CDK2-IN-1 (compound 14d) 是一种有效的HDAC1HDAC2CDK2抑制剂,IC50分别为 70.7,23.1 和 0.80 μM。HDAC1/2 and CDK2-IN-1 可阻断细胞周期,诱导细胞凋亡 (apoptosis)。HDAC1/2 and CDK2-IN-1 表现出良好的体内抗肿瘤活性。
生物活性

HDAC1/2 and CDK2-IN-1 (compound 14d) is a potentHDAC1,HDAC2andCDK2dual inhibitor, withIC50values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induceapoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirablein vivoantitumor activity[1].

IC50& Target[1]

HDAC1

70.7 nM (IC50)

HDAC2

23.1 nM (IC50)

CDK2

0.80 nM (IC50)

体外研究
(In Vitro)

HDAC1/2 and CDK2-IN-1 (compound 14d) shows excellent antiproliferative activities against H460, A375, HepG2, HCT116 and Hela cells with IC50values of 1.59, 0.47, 0.86, 0.58 and 1.05 μM, respectively[1].
HDAC1/2 and CDK2-IN-1 (0.5 μM, 48 h) significantly inhibits the migration of H460 and A375 cells[1].
HDAC1/2 and CDK2-IN-1 (0-2 μM, 24 h) significantly blocks the cell cycle in the G2/M phase[1].
HDAC1/2 and CDK2-IN-1 (0-2 μM, 48 h) promotes cancer cell apoptosis in a dose-dependent manner[1].
HDAC1/2 and CDK2-IN-1 (1 μM, 12 h) inhibits CDK2 and HDAC activity, causing cancer cell death[1].
HDAC1/2 and CDK2-IN-1 (1 μM, 24 h) strongly increases ROS levels in A375 cells, causes cancer cell death by improving intracellular ROS levels[1].

Cell Cycle Analysis

Cell Line:A375, HCT116, H460 and Hela cells[1]
Concentration:0, 0.5, 1, 2 μM
Incubation Time:24 h
Result:Significantly blocked the cell cycle, induced a loss of G0/G1 phase cells and an increase of G2/M phase cells, led to an apparent accumulation of cells in G2/M phase at 0.5 μM (A375, the percentage from 13.70 to 57.03%; HCT116, from 27.46 to 76.99%; Hela, from 7.89% to 51.85%).

Apoptosis Analysis

Cell Line:A375, HCT116, H460 and Hela cell lines[1]
Concentration:0, 0.5, 1, 2 μM
Incubation Time:48 h
Result:Promoted cancer cell apoptosis in a dose-dependent manner, with the apoptosis rates of 91.99% (A375), 89.60% (HCT116), 59.10% (H460), and 22.36% (Hela) respectively at the concentration of 2 μM.

Immunofluorescence

Cell Line:A375 cells[1]
Concentration:1 μM
Incubation Time:12 h
Result:Significantly inhibited CDK2 and increased the acetylation level of histone H3, inhibited CDK2 and HDAC activity, causing cancer cell death.
体内研究
(In Vivo)

HDAC1/2 and CDK2-IN-1 (BALB/c nude mice, 0-100 mg/kg, IP, once daily for 21 days) significantly inhibits the tumor growth[1].
HDAC1/2 and CDK2-IN-1 (compound 14d) (ICR mice; 4 mg/kg, IV; 20 mg/kg, IP) exhibits desirable pharmacokinetic properties[1].
Pharmacokinetic Parameters of HDAC1/2 and CDK2-IN-1 in male ICR mice[1].

Dose (mg/kg)420
AdministrationIVIP
T1/2(h)1.482.84
Tmax(h)2
Cmax(ng/mL)1360
AUC0-t(ng/mL*h)28507240
MRT0-t(h)0.5634.54
CL (mL/(min/kg))23.3
F (%)50.8

Animal Model:Male ICR mice (n = 9)[1]
Dosage:4 mg/kg (IV), 20 mg/kg (IP)
Administration:IV, IP, once (Pharmacokinetic Analysis)
Result:Exhibited desirable pharmacokinetic properties.
Animal Model:BALB/c nude mice (5-6 weeks, HCT116 xenograft model)[1]
Dosage:0, 25, 50 and 100 mg/kg
Administration:IP, once daily for 21 days
Result:Significantly inhibited the tumor growth, the tumor growth inhibitions were 28%, 40% and 44% at doses of 25, 50 and 100 mg/kg, respectively.
分子量

483.95

Formula

C26H22ClN7O

CAS 号

2418559-01-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.